Please select the option that best describes you:
What is your recommended adjuvant approach to resected NSCLC with both PD-L1>1% and EGFR mutation?
What would you do for a patient with a non-EGFR actionable mutation?
IMpower010 included EGFR and ALK mutated NSCLC. Is there any concern in the use of adjuvant immunotherapy for these patients?
Answer from: Medical Oncologist at Academic Institution
IMpower010 included patients with EGFR mutations, which made up about 10% of the patients enrolled in the trial. In the subgroup analysis of EGFR patients whose tumors expressed PDL1 ≥1%, the HR of 0.57 favored atezolizumab, but had a wide confidence interval (95% CI, 0.26-1.24). Other studies of...
Sign in or Register to read more
Answer from: Medical Oncologist at Community Practice
For patients with EGFR exon 19del and L858R mutations, I discuss the benefit in preventing disease recurrence by 3 years of osimertinib therapy following completion of adjuvant chemotherapy and I offer the treatment. I do not offer adjuvant atezolizumab to those patients. Though patients with E...